Mesoblast Limited (MESO)Healthcare | Biotechnology | Melbourne, Australia | NasdaqGS
16.22 USD
+0.78
(5.052%)
⇧
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:49 a.m. EDT
The investment case for Mesoblast is currently bifurcated between a compelling catalyst-driven trade and a fundamentally distressed biotech profile. On the short end, the market is pricing in a major event: the company's Rexlemestrocel-L product has entered FDA modular review, a critical milestone that could unlock significant value. This is corroborated by the options chain, where traders are aggressively buying calls at strikes well above the current price, betting on a rapid re-rating upon regulatory approval. However, the long-term outlook remains precarious. The company is burning cash rapidly, with negative operating cash flow and gross margins, and relies entirely on future drug approvals for survival. While the revenue growth rate is positive, the absolute scale is negligible, and the balance sheet is fragile. The lack of a dividend and the high volatility inherent in pre-revenue biotech stocks suggest that while the risk/reward ratio is attractive for a tactical play on the FDA decision, the underlying business quality does not yet support a permanent hold at these valuations. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.043800 |
| AutoETS | 0.043812 |
| AutoARIMA | 0.043812 |
| MSTL_79 | 0.048827 |
| MSTL | 0.049690 |
| MSTL_97 | 0.067134 |
| MSTL_79_97 | 0.090119 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.46 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.630 |
| Excess Kurtosis | -0.61 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 23.516 |
| Revenue per Share | 0.51 |
| Market Cap | 2,096,962,944 |
| Forward P/E | -231.71 |
| Beta | 0.80 |
| Profit Margins | -144.33% |
| Website | https://www.mesoblast.com |
As of July 11, 2026, 5:49 a.m. EDT: Speculators are positioning for a significant upside move, evidenced by heavy open interest in out-of-the-money calls at strikes of 18 and 25 for the July expiration, and substantial long-dated call volume at strikes of 20 and 25. Conversely, put activity is concentrated near the money or slightly out-of-the-money, suggesting a defensive stance rather than a bearish bet. The skew indicates a speculative expectation of a rally driven by the FDA review progress.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.47992706 |
| Address1 | 55 Collins Street |
| Address2 | Level 38 |
| All Time High | 106.34 |
| All Time Low | 1.61 |
| Ask | 20.58 |
| Ask Size | 2 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 238,290 |
| Average Daily Volume3 Month | 188,809 |
| Average Volume | 188,809 |
| Average Volume10Days | 238,290 |
| Beta | 0.798 |
| Bid | 11.82 |
| Bid Size | 2 |
| Book Value | 4.46 |
| City | Melbourne |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Australia |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.22 |
| Current Ratio | 1.581 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 16.48 |
| Day Low | 16.06 |
| Debt To Equity | 23.516 |
| Earnings Call Timestamp End | 1,772,143,200 |
| Earnings Call Timestamp Start | 1,772,143,200 |
| Earnings Timestamp End | 1,772,139,600 |
| Earnings Timestamp Start | 1,772,139,600 |
| Ebitda | -64,339,000 |
| Ebitda Margins | -0.98402 |
| Enterprise To Ebitda | -32.564 |
| Enterprise To Revenue | 32.044 |
| Enterprise Value | 2,095,140,224 |
| Eps Current Year | -0.475 |
| Eps Forward | -0.07 |
| Eps Trailing Twelve Months | -0.77 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 61 3 9639 6030 |
| Fifty Day Average | 14.6822 |
| Fifty Day Average Change | 1.5377989 |
| Fifty Day Average Change Percent | 0.104738995 |
| Fifty Two Week Change Percent | 47.992706 |
| Fifty Two Week High | 21.5 |
| Fifty Two Week High Change | -5.2800007 |
| Fifty Two Week High Change Percent | -0.24558143 |
| Fifty Two Week Low | 10.96 |
| Fifty Two Week Low Change | 5.2599993 |
| Fifty Two Week Low Change Percent | 0.47992694 |
| Fifty Two Week Range | 10.96 - 21.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,263,997,800,000 |
| Float Shares | 83,383,668 |
| Forward Eps | -0.07 |
| Forward P E | -231.71428 |
| Free Cashflow | -69,438,336 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 81 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.35535 |
| Gross Profits | -23,234,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.05051 |
| Held Percent Institutions | 0.02804 |
| Implied Shares Outstanding | 129,282,554 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,704,844,800 |
| Last Split Factor | 1:2 |
| Long Business Summary | Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. |
| Long Name | Mesoblast Limited |
| Market | us_market |
| Market Cap | 2,096,962,944 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_20356678 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -94,370,000 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 2,094,190,104 |
| Number Of Analyst Opinions | 2 |
| Open | 16.155 |
| Operating Cashflow | -59,643,000 |
| Operating Margins | -0.55158 |
| Payout Ratio | 0.0 |
| Phone | 61 3 9639 6036 |
| Previous Close | 15.44 |
| Price Eps Current Year | -34.147366 |
| Price Hint | 2 |
| Price To Book | 3.6367712 |
| Price To Sales Trailing12 Months | 32.0715 |
| Profit Margins | -1.44332 |
| Quick Ratio | 1.353 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | 0.78 |
| Regular Market Change Percent | 5.05181 |
| Regular Market Day High | 16.48 |
| Regular Market Day Low | 16.06 |
| Regular Market Day Range | 16.06 - 16.48 |
| Regular Market Open | 16.155 |
| Regular Market Previous Close | 15.44 |
| Regular Market Price | 16.22 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 342,062 |
| Return On Assets | -0.06163 |
| Return On Equity | -0.18219 |
| Revenue Growth | 15.268 |
| Revenue Per Share | 0.51 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 129,282,554 |
| Shares Percent Shares Out | 0.024 |
| Shares Short | 3,103,325 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,061,116 |
| Short Name | Mesoblast Limited |
| Short Percent Of Float | 0.032899998 |
| Short Ratio | 17.15 |
| Source Interval | 15 |
| State | VIC |
| Symbol | MESO |
| Target High Price | 35.0 |
| Target Low Price | 35.0 |
| Target Mean Price | 35.0 |
| Target Median Price | 35.0 |
| Total Cash | 129,975,000 |
| Total Cash Per Share | 1.009 |
| Total Debt | 135,144,000 |
| Total Revenue | 65,384,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.77 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 16.1876 |
| Two Hundred Day Average Change | 0.03240013 |
| Two Hundred Day Average Change Percent | 0.0020015403 |
| Type Disp | Equity |
| Volume | 342,062 |
| Website | https://www.mesoblast.com |
| Zip | 3,000 |